Unity Health Toronto

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
火曜日, 4月 16, 2024
Pillar, Phase, Patient, Reperfusion, Kidney, Inflammation, Arch, Hospital, Randomness, OTCQB, Science Advances, IRI, TMX Group, Kidney disease, Research, Acute kidney injury, Ischemia, Yolo Bypass, Oxygen, Liver, User experience, Unity Health Toronto, Injury, Regeneration, Placebo-controlled study, AKI, Ethics, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no therapeutic treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Unity Health Toronto partners with Cure51 to identify the biological characteristics of survivors of incurable cancers

Retrieved on: 
水曜日, 4月 24, 2024
Cancer, Providence Healthcare, Hope, Hospital, Survival, St. Michael's Hospital, Partnership, Research, Survivor, Glioblastoma, Therapy, Patient, Unity Health Toronto, Diagnosis, Health, Pharmaceutical industry

As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project.

Key Points: 
  • As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project.
  • Cure51 is building the first global clinical and multi omics database of exceptional survivors with over 1100 patients from all continents and ethnic origins.
  • "Cure51 is thrilled to welcome Unity Health Toronto to our growing network of medical partners," said Simon Istolainen, Cure51 co-founder and Chief Strategy and Scientific Network Officer.
  • Unity Health Toronto operates three major hospitals – St. Michael's Hospital, St. Joseph's Health Centre, and Providence Healthcare – each renowned for its commitment to compassionate care and groundbreaking research.

Unity Health Toronto partners with Cure51 to identify the biological characteristics of survivors of incurable cancers

Retrieved on: 
水曜日, 4月 24, 2024
Cancer, Providence Healthcare, Hope, Hospital, Survival, St. Michael's Hospital, Partnership, Research, Survivor, Glioblastoma, Therapy, Patient, Unity Health Toronto, Diagnosis, Health, Pharmaceutical industry

As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project.

Key Points: 
  • As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project.
  • Cure51 is building the first global clinical and multi omics database of exceptional survivors with over 1100 patients from all continents and ethnic origins.
  • "Cure51 is thrilled to welcome Unity Health Toronto to our growing network of medical partners," said Simon Istolainen, Cure51 co-founder and Chief Strategy and Scientific Network Officer.
  • Unity Health Toronto operates three major hospitals – St. Michael's Hospital, St. Joseph's Health Centre, and Providence Healthcare – each renowned for its commitment to compassionate care and groundbreaking research.

National KOLs converge that data management is the hinge factor for reshaping healthcare in Canada

Retrieved on: 
木曜日, 10月 12, 2023
Unity Health Toronto, AI, Partner, McKinsey & Company, Health, Big data, The Ottawa Hospital, Data, Privacy, Research, Medical device, Health care

“As our healthcare system emerges from the pandemic, the time to innovate and embrace healthcare transformation has never been more important,” declared Cameron Love, President, and CEO at Ottawa Hospital, who was a speaker in the first panel “Innovative Healthcare Management”.

Key Points: 
  • “As our healthcare system emerges from the pandemic, the time to innovate and embrace healthcare transformation has never been more important,” declared Cameron Love, President, and CEO at Ottawa Hospital, who was a speaker in the first panel “Innovative Healthcare Management”.
  • The session “A Forward-looking View of Big Data and AI in the New Medicine” pointed out how Canada is leading AI research and the importance of the interpretation of that Data.
  • “Earlier we talked about the transformation needed in Healthcare, to really improve the services, AI has the potential to make a real exponential change.
  • This event is part of the Healthcare Innovation Series that Bamberg Health hosts around the world looking to connect key decision-makers to achieve a real positive impact on healthcare.

Hazel Claxton Appointed to Bank of Montreal Board of Directors

Retrieved on: 
水曜日, 8月 30, 2023
Canada, Acquisition, Unity Health Toronto, Executive, Institute of Corporate Directors, University, Chairperson, C40 Cities Climate Leadership Group, Bank of Montreal, Human Capital, Telus Corporation, Telus Health, Strategic planning, LifeWorks, Accounting, Chartered accountant, Partner, Knowledge, Bank, TELUS, Queen's University, Commerce, Management

TORONTO, Aug. 30, 2023 /PRNewswire/ - Bank of Montreal today announced the appointment of Hazel Claxton, former Executive Vice-President and Chief Human Resources Officer of Morneau Shepell Inc. (now part of TELUS Health), to its Board of Directors.

Key Points: 
  • TORONTO, Aug. 30, 2023 /PRNewswire/ - Bank of Montreal today announced the appointment of Hazel Claxton, former Executive Vice-President and Chief Human Resources Officer of Morneau Shepell Inc. (now part of TELUS Health), to its Board of Directors.
  • "We are pleased to welcome Hazel to the Board of Directors," said George A.
  • Ms. Claxton currently sits on the boards of Allied Properties REIT, TELUS Corporation, University Pension Plan Ontario and Unity Health Toronto.
  • Ms. Claxton holds a Bachelor of Commerce (Honours) from Queen's University and the ICD.D designation from the Institute of Corporate Directors.

Hazel Claxton Appointed to Bank of Montreal Board of Directors

Retrieved on: 
水曜日, 8月 30, 2023
Canada, Acquisition, Unity Health Toronto, Executive, Institute of Corporate Directors, University, Chairperson, C40 Cities Climate Leadership Group, Bank of Montreal, Human Capital, Telus Corporation, Telus Health, Strategic planning, LifeWorks, Accounting, Chartered accountant, Partner, Knowledge, Bank, TELUS, Queen's University, Commerce, Management

TORONTO, Aug. 30, 2023 /PRNewswire/ -- Bank of Montreal today announced the appointment of Hazel Claxton, former Executive Vice-President and Chief Human Resources Officer of Morneau Shepell Inc. (now part of TELUS Health), to its Board of Directors.

Key Points: 
  • TORONTO, Aug. 30, 2023 /PRNewswire/ -- Bank of Montreal today announced the appointment of Hazel Claxton, former Executive Vice-President and Chief Human Resources Officer of Morneau Shepell Inc. (now part of TELUS Health), to its Board of Directors.
  • "We are pleased to welcome Hazel to the Board of Directors," said George A.
  • Ms. Claxton currently sits on the boards of Allied Properties REIT, TELUS Corporation, University Pension Plan Ontario and Unity Health Toronto.
  • Ms. Claxton holds a Bachelor of Commerce (Honours) from Queen's University and the ICD.D designation from the Institute of Corporate Directors.

More than 75% of Canadians had immunity to SARS-CoV-2 due to infection by March 2023

Retrieved on: 
月曜日, 8月 14, 2023
Infection, McGill University Health Centre, Unity Health Toronto, Omicron, University, Data management, SARS-CoV-2, Public, Public Health Agency of Canada, COVID-19, Policy, Immunity, University of Ottawa, Research, Antibody, Global Health, CITF, Blood, School, ISCB Senior Scientist Award, McGill University, Research institute, Ageing, Hospital, Saskatchewan Health Authority, Public Health Agency, ST, Canadian Medical Association Journal, Geography, Pharmaceutical industry, Vaccine, Canadian Blood Services, CMAJ

Today, the COVID-19 Immunity Task Force (CITF) published the most comprehensive peer-reviewed analysis of pan-Canadian seroprevalence estimates in CMAJ (Canadian Medical Association Journal) .

Key Points: 
  • Today, the COVID-19 Immunity Task Force (CITF) published the most comprehensive peer-reviewed analysis of pan-Canadian seroprevalence estimates in CMAJ (Canadian Medical Association Journal) .
  • Three time periods were analyzed: pre-vaccination (March 2020 to November 2020); vaccine roll-out (December 2020 to November 2021); and the Omicron waves (December 2021 to March 2023).
  • The low infection rates in Canada before Omicron were observed in other high-income countries in Europe and North America as well.
  • “By March 2023, roughly 80% of adults aged 18-25 had evidence of a previous infection.

Leading International Cardiothoracic Surgeon & Researcher Named System Director of Aortic Surgery at NYU Langone Health

Retrieved on: 
木曜日, 8月 3, 2023
University, Education, NYU Langone Health, NYU, Cardiovascular disease, New York University Grossman School of Medicine, Aortic aneurysm, MBA, Research, Doctor of Philosophy, Science, St. Michael's Hospital, Patient, Division, Pediatrics, Unity Health Toronto, Michael (archangel), Faculty, Hospital, Saint Michael, Dentistry, Brain, MD

NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Mark D. Peterson, MD, PhD, an internationally recognized cardiothoracic surgeon and researcher, has been named system director of aortic surgery at NYU Langone Heart and professor in the Department of Cardiothoracic Surgery at NYU Grossman School of Medicine, effective August 1.

Key Points: 
  • NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Mark D. Peterson, MD, PhD, an internationally recognized cardiothoracic surgeon and researcher, has been named system director of aortic surgery at NYU Langone Heart and professor in the Department of Cardiothoracic Surgery at NYU Grossman School of Medicine, effective August 1.
  • "His clinical skill in complex aortic surgery, his commitment to patient outcomes, and his dedication to training future cardiothoracic surgeons align with the core mission of the Department of Cardiothoracic Surgery.
  • Within NYU Langone Heart, Dr. Peterson will work with a team of multidisciplinary specialists who address and determine the best treatments for aortic disease.
  • At NYU Langone's Center for Complex Aortic Disease , renowned cardiothoracic and vascular experts bring together their decades of surgical expertise to repair the hardest-to-treat types of aortic aneurysm, including aortic root, aortic arch, and thoracoabdominal aneurysms.

Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians

Retrieved on: 
火曜日, 7月 4, 2023
Health, Medical Devices, Diabetes, Technology, Health Technology, Wearables, Mobile Technology, Hardware, CGM, Unity Health Toronto, Compatibility, Quality of life, Credit Valley Hospital, Multimedia, Trillium Health Partners, Hypoglycemia, G6, Patient, DXCM, Health Canada, Family, Caregiver, Disease, Medical device, Dexcom

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.

Key Points: 
  • Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.
  • View the full release here: https://www.businesswire.com/news/home/20230704730937/en/
    Dexcom G7 receives Health Canada approval.
  • Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians.
  • Dexcom Canada is working diligently to bring Dexcom G7 to Canadians living with diabetes by the end of 2023.

Brain Cancer Canada Awards St. Michael’s Hospital $100,000 Grant for Advanced DNA Sequencer Technology

Retrieved on: 
水曜日, 5月 31, 2023
Canada, DNA, Unity Health Toronto, Partnership, Cancer, Research, Brain, Brain tumor, Acquisition, Patient, Hospital, BCC, Medical imaging

TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s leading charitable organization dedicated to brain cancer research, has announced a $100,000 grant to St. Michael’s Hospital, a site of Unity Health Toronto.

Key Points: 
  • TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s leading charitable organization dedicated to brain cancer research, has announced a $100,000 grant to St. Michael’s Hospital, a site of Unity Health Toronto.
  • The funds will facilitate the acquisition of a top-of-the-line, next-generation DNA sequencer, technology that will allow St. Michael’s to develop and test innovative new treatment protocols for the toughest forms of brain cancer.
  • “It will empower us to customize treatments to individual patients, which is a major step towards improved patient outcomes.”
    For Brain Cancer Canada, this gift to St. Michael’s brain cancer program is a central element of a push to increase treatment options for brain cancer patients.
  • “Our goal at BCC is to bring more effective new treatments to patients,” said Angela Scalisi, Chair of Brain Cancer Canada.